Previous Page  2 / 4 Next Page
Information
Show Menu
Previous Page 2 / 4 Next Page
Page Background

allied

academies

Page 13

Notes:

Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN:2249-622X | Volume 9

July 05-06, 2019 | Paris, France

Pharmaceutics and Advanced Drug Delivery Systems

2

nd

International Conference and Exhibition on

A Novel Intracutaneous Microneedle Delivery System for

zolmitriptan has been developed by Zosano. This delivery

system provides:

• Rapid non oral delivery and pulsatile PK profile

• Room temperature stable formulations

• Patient friendly alternative to injection

• Versatile delivery platform capable of delivering large and

small molecules, and vaccines

In a recent clinical trial zolmitriptan intracutaneous

microneedle delivery system was highly effective for the

treatment of migraine, with statistical significance compared

to placebo achieved for the two co-primary endpoints of pain

freedom at 2 hours and most bothersome symptom absence

at 2 hours. The results in our clinical study show the usefulness

of intracutaneous microneedle delivery system for delivering

zolmitriptan rapidly and yielding pharmacologic effects

quickly which may be a significant advantage compared to

nasal and oral formulations of zolmitriptan. In combination

with our ongoing long-term safety study we believe this

trial will form the basis for approval. In addition, patients

have demonstrated that they are able to reliably apply the

intracutaneous patches and find the product convenient and

easy to use.

Speaker Biography

Hayley Lewis attained her Bachelors in Pharmaceutical Sciences from

the University of Greenwich in England, and has attained several

management diplomas from Kellogg School of Management, as well as

Stanford’sGraduateSchoolofBusiness.Shecurrentlyholdsthepositionof

Senior Vice President, Operations at Zosano Pharma where she oversees

the functional areas of Nonclinical, R&D, Analytical Development

and QC, Engineering, Manufacturing, and Regulatory Affairs. Prior to

Zosano, she has spent her 26-year career in the field of Drug Delivery

at Depomed, Inc, now Assertio Therapeutics, Nektar Therapeutics,

Aradigm, GlaxoSmithKline, and Merck-Lipha Pharmaceuticals, involved

the areas of Product Development, and Regulatory Affairs and Quality.

She has published articles for Drug Development and Delivery,

Pharmaceutical Technology, as well as co-authored papers published

in Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.

e:

hlewis@zosanopharma.com

Hayley Lewis

Zosano Pharma Corporation, USA

A novel intracutaneous microneedle delivery system for the

treatment of acute migraine

Hayley Lewis

, Asian J Biomed Pharmaceut Sci, | ISSN: 2249-622X

Volume 9